RxDoctor Payments Data

David Rapp, MD

Urology · Charlottesville, VANPI 1639373269

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 18 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Boston Scientific at 35.7% of the total. 2025 is the largest year on record at $228, 8.8 times the $26 reported in 2019. That places this record below the midpoint for urology clinicians in VA, where the typical reported total is $2,551.

$959in general payments, 2019–2025

Across 18 payments — averaging $53.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$342
  • Medtronic$335
  • KARL Storz Endoscopy-america$139
  • Johnson & Johnson$89
  • Olympus America Inc.$23
  • Procept Biorobotics Corporation$20
  • plus $11 from 1 others
$8,100in research payments, 2019–2025

Across 3 payments — averaging $2700.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boston Scientific$8K

What the payments were for

  • Food & beverage$959100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$959 in reported general payments places this provider in the 30th percentile of 300 urology providers in Virginia.

See all urology providers in Virginia →

Medicare billing

Part B allowed, 2024
$21,598
Medicare patients
141
Services billed
195

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron51$32,980
GemtesaVibegron14$6,693
Fesoterodine Fumarate ErFesoterodine Fumarate47$2,756
Tamsulosin Hcl23$350
Solifenacin Succinate29$306
Oxybutynin Chloride ErOxybutynin Chloride11$171

Paid to pharmacies, not to this prescriber.

Other urology in Charlottesville

See the full list for Virginia →

Where these figures come from

Is this you, or does something look wrong? →